Moberg Pharma AB (FRA:MB8) EPS without NRI: €-0.05 (TTM As of Mar. 2026)


FRA:MB8 Moberg Pharma AB FRA:MB8
59 GF Score
Price €0.81
GF Value €1.06
! 1 Warning Sign
View Full Analysis

What is Moberg Pharma AB EPS without NRI?

Moberg Pharma AB FRA:MB8 +0.50% 59 EPS without NRI is €-0.05 as of Mar. 2026. GuruFocus rates FRA:MB8 with a GF Score™ of 59/100 and a GF Value™ of €1.06. The stock has 1 warning sign investors should review. Among 786 Drug Manufacturers companies, Moberg Pharma AB ranks worse than 92.24% on this metric.

Moberg Pharma AB's earnings per share without non-recurring items for the three months ended in Mar. 2026 was €-0.00. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.05.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -38.60% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -25.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Moberg Pharma AB's EPS without NRI or its related term are showing as below:

FRA:MB8' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -52.8   Med: 10.05   Max: 61.9
Current: -38.6

During the past 13 years, Moberg Pharma AB's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 61.90% per year. The lowest was -52.80% per year. And the median was 10.05% per year.

FRA:MB8's 3-Year EPS without NRI Growth Rate is ranked worse than
92.24% of 786 companies
in the Drug Manufacturers industry
Industry Median: 9.65 vs FRA:MB8: -38.60

Moberg Pharma AB's EPS (Diluted) for the three months ended in Mar. 2026 was €-0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.05.

Moberg Pharma AB's EPS (Basic) for the three months ended in Mar. 2026 was €-0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.05.


Moberg Pharma AB  (FRA:MB8) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Moberg Pharma AB EPS without NRI Related Terms


Moberg Pharma AB EPS without NRI Historical Data

* Premium members only.

The historical data trend for Moberg Pharma AB's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moberg Pharma AB EPS without NRI Chart

Moberg Pharma AB Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec21 Dec22 Dec23 Dec24
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.89 -0.25 -0.13 -0.12 -0.59

Moberg Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.02 -0.01 -0.03 -0.00

FRA:MB8 vs ZTS, UTHR: EPS without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moberg Pharma AB PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Moberg Pharma AB's PE Ratio without NRI falls into.


FRA:MB8
59GF Score
Moberg Pharma AB FRA:MB8
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moberg Pharma AB EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of €-0.05 mean?
Moberg Pharma AB (FRA:MB8) has a EPS without NRI of €-0.05 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Moberg Pharma AB and its competitors. According to the industry distribution chart, Moberg Pharma AB ranks #725 out of 786 companies in the Drug Manufacturers industry, placing it in the top 92.2%.
Is Moberg Pharma AB's EPS without NRI too high?
Moberg Pharma AB's current EPS without NRI is €-0.05. Based on the distribution chart, Moberg Pharma AB ranks #725 out of 786 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Moberg Pharma AB has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's EPS without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Moberg Pharma AB ranks #725 out of 786 companies for EPS without NRI. This places Moberg Pharma AB in the lower half of its industry. The industry median EPS without NRI is 9.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.65, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Moberg Pharma AB and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moberg Pharma AB's current EPS without NRI is €-0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Moberg Pharma AB (FRA:MB8) has a current EPS without NRI of €-0.05. The stock's GF Value™ is €1.06, compared to a current price of €0.81 — trading 24% below its estimated fair value. The current EPS without NRI is €-0.05. Moberg Pharma AB's overall GF Score™ is 59/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Moberg Pharma AB (FRA:MB8), the current EPS without NRI is €-0.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Moberg Pharma AB (FRA:MB8) Overvalued in 2026?

Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued. The current stock price of €0.81 is trading 24% below its estimated GF Value™ of €1.06.

Key valuation signals for FRA:MB8:

  • EPS without NRI: €-0.05
  • GF Value™: €1.06 vs. price of €0.81 (24% below fair value)
  • GF Score™: 59/100 with 1 warning sign

No single metric tells the full story. See the FRA:MB8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Moberg Pharma AB Business Description

Other Exchanges MBGPF:USAMOB:Sweden
Address Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
59GF Score

Get the complete analysis for FRA:MB8

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.81
Price
€1.06
GF Value